Osimertinib
Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) primarily used in the treatment of advanced non-small cell lung cancer (NSCLC) harboring specific EGFR mutations, particularly the exon 19 deletions and the L858R point mutation.
Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) primarily used in the treatment of advanced non-small cell lung cancer (NSCLC) harboring specific EGFR mutations, particularly the exon 19 deletions and the L858R point mutation. It functions by irreversibly binding to the EGFR tyrosine kinase domain, inhibiting downstream signaling pathways that promote tumor growth and survival. This selective inhibition leads to reduced proliferation of cancer cells and has been associated with improved clinical outcomes in patients with EGFR-mutated NSCLC.
The drug's significance lies in its ability to overcome resistance mechanisms that limit the efficacy of earlier-generation EGFR TKIs, such as gefitinib and erlotinib. Osimertinib has been shown to provide substantial benefits in terms of progression-free survival (PFS) and overall survival in various clinical settings, making it a cornerstone in the management of EGFR-mutated lung cancer.
Where the papers sit
19 papers from the last 6 months study osimertinib directly · updated from PubMed 12 Oct 2026
Study type 5 clinical trials · 4 observational · 5 human data · 4 preclinical · 1 unclassified
Themes 4 themes · 2 new directions
-
Advanced EGFR Lung Cancer
Front-line osimertinib is being refined by EGFR subtype, TP53 co-mutation, EGFR amplification and muscle loss rather than treated as a uniform regimen. Outcomes center on progression-free survival and hazard differences in advanced NSCLC, including uncommon exon 19 deletions and brain metastases. Chemotherapy combinations and post-progression selumetinib are being explored for selected genomic contexts, while re-escalation offers a rescue approach. Pneumonitis, drug exposure and acquired resistance remain key limits.
12 papers · 63.2%
-
Stage III EGFR Lung Cancer
Consolidation osimertinib after definitive chemoradiotherapy is extending targeted treatment into unresectable stage III EGFR-mutated NSCLC. The LAURA evidence focuses on safety and patient-reported outcomes alongside disease control, rather than metastatic first-line therapy. Interstitial lung disease and pneumonitis remain the central safety concerns. The open question is whether durable benefit can be maintained without worsening symptoms or quality of life.
2 papers · 10.5%
-
Osimertinib Resistance
Osimertinib is being positioned as a practical second-line option after earlier EGFR TKIs even when T790M status is unknown. Resistance research is shifting attention beyond EGFR sequence changes toward altered sphingolipid metabolism in NSCLC. The clinical evidence supports feasibility, while the metabolic findings remain mechanistic and require validation. Biomarker-guided sequencing and ways to overcome metabolic resistance remain unresolved.
2 papers · 10.5%
-
Others — Dual Drug Strategies
Drug development spans dual-activation prodrugs, dual-target UFMylation inhibition and pharmacokinetic modeling of savolitinib with osimertinib. The applications range from chemical delivery to glioblastoma immune-tumor reprogramming and EGFR-driven lung cancer. Combination exposure, trough concentrations and covariates are quantified in the clinical study, whereas the other work is preclinical. No single disease or translational direction unifies the cluster.
3 papers · 15.8%
Osimertinib is repurposed as a covalent UFMylation inhibitor in glioblastoma
The glioblastoma study treats osimertinib, ordinarily presented as an EGFR T790M-selective inhibitor for EGFR-mutant lung cancer, as a covalent inhibitor of the UFMylation E3-ligase component DDRGK1 instead. By disrupting the DDRGK1–UFL1 interaction, osimertinib suppresses UFMylation, induces ER stress, affects macrophage polarization, and produces tumor regression in glioblastoma models, establishing a non-EGFR therapeutic role for the drug 42472853Jul.
Osimertinib is incorporated as a conditionally activated payload in a dual prodrug system
The bioorthogonal prodrug study uses osimertinib not as a directly administered EGFR-targeted therapy but as one covalent inhibitor payload coactivated with doxorubicin or CA4 through a tandem retro-Cope/Cope-elimination strategy. This assigns osimertinib a new role as a component of a dual-activation chemical-delivery platform for combination therapy 42138023May.
Papers
The 19 papers from the last 6 months that study osimertinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Advanced EGFR Lung Cancer (12)
- Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) · 3 Sept 2026 PMID 42691830
- The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands) · 27 Aug 2026 PMID 42660014
- Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. JAMA · 10 Aug 2026 PMID 42574006
- Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib. Clinical cancer research : an official journal of the American Association for Cancer Research · 14 Jul 2026 PMID 42446521
- Rescue of Suprasellar Metastasis of EGFR-mutant NSCLC by Daily Osimertinib Re-escalation With Filgrastim Support. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379747
- Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function. Proceedings of the National Academy of Sciences of the United States of America · 17 Jun 2026 PMID 42308042
- Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD. European journal of cancer (Oxford, England : 1990) · 27 May 2026 PMID 42202477
- A real-world pharmacovigilance study of four anti-non-small cell lung cancer drugs using the WHO-VigiAccess database. Medicine · 23 May 2026 PMID 42175505
- Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH). Cancer biology & medicine · 22 May 2026 PMID 42170792
- USP48 stabilizes YBX1 to enforce a Wnt-driven stemness circuit and osimertinib resistance in EGFR-mutant NSCLC. Cancer letters · 16 May 2026 PMID 42142703
- Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study. Anticancer research · 28 Apr 2026 PMID 42049362
- Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC. European journal of cancer (Oxford, England : 1990) · 17 Apr 2026 PMID 41997038
Stage III EGFR Lung Cancer (2)
- Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study. Lung cancer (Amsterdam, Netherlands) · 15 Jun 2026 PMID 42296617
- Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy. European journal of cancer (Oxford, England : 1990) · 22 Apr 2026 PMID 42019226
Osimertinib Resistance (2)
- Empirical Osimertinib as a Second-Line Treatment Is a Viable Option Following First- and Second-Generation TKI Therapy With Unknown EGFR Status in Treated Non-Small Cell Lung Cancer: A Retrospective Study. Cancer medicine · 25 Apr 2026 PMID 42032945
- Altered Sphingolipid Metabolism is Associated with Osimertinib Resistance in Nonsmall-Cell Lung Cancer. Journal of proteome research · 16 Apr 2026 PMID 41988688
Others — Dual Drug Strategies (3)
- Population Pharmacokinetics and Exposure-Response Analyses of Savolitinib Alone or in Combination With Osimertinib in Patients With Locally Advanced or Metastatic Solid Tumors. Clinical and translational science · 25 Aug 2026 PMID 42638263
- Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression. Signal transduction and targeted therapy · 19 Jul 2026 PMID 42472853
- A Bioorthogonal Prodrug-Prodrug Strategy for Dual Activation Via Retro-Cope/Cope Elimination. Organic letters · 15 May 2026 PMID 42138023
By study type
Clinical trials (5)
- Population Pharmacokinetics and Exposure-Response Analyses of Savolitinib Alone or in Combination With Osimertinib in Patients With Locally Advanced or Metastatic Solid Tumors. Clinical and translational science · 25 Aug 2026 PMID 42638263
- Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. JAMA · 10 Aug 2026 PMID 42574006
- Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study. Lung cancer (Amsterdam, Netherlands) · 15 Jun 2026 PMID 42296617
- Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD. European journal of cancer (Oxford, England : 1990) · 27 May 2026 PMID 42202477
- Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy. European journal of cancer (Oxford, England : 1990) · 22 Apr 2026 PMID 42019226
Observational studies and case reports (4)
- Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) · 3 Sept 2026 PMID 42691830
- Rescue of Suprasellar Metastasis of EGFR-mutant NSCLC by Daily Osimertinib Re-escalation With Filgrastim Support. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379747
- Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study. Anticancer research · 28 Apr 2026 PMID 42049362
- Empirical Osimertinib as a Second-Line Treatment Is a Viable Option Following First- and Second-Generation TKI Therapy With Unknown EGFR Status in Treated Non-Small Cell Lung Cancer: A Retrospective Study. Cancer medicine · 25 Apr 2026 PMID 42032945
Human data, design not indexed (5)
- The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands) · 27 Aug 2026 PMID 42660014
- Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib. Clinical cancer research : an official journal of the American Association for Cancer Research · 14 Jul 2026 PMID 42446521
- A real-world pharmacovigilance study of four anti-non-small cell lung cancer drugs using the WHO-VigiAccess database. Medicine · 23 May 2026 PMID 42175505
- A Bioorthogonal Prodrug-Prodrug Strategy for Dual Activation Via Retro-Cope/Cope Elimination. Organic letters · 15 May 2026 PMID 42138023
- Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC. European journal of cancer (Oxford, England : 1990) · 17 Apr 2026 PMID 41997038
Preclinical: animal, cell and lab studies (4)
- Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression. Signal transduction and targeted therapy · 19 Jul 2026 PMID 42472853
- Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function. Proceedings of the National Academy of Sciences of the United States of America · 17 Jun 2026 PMID 42308042
- USP48 stabilizes YBX1 to enforce a Wnt-driven stemness circuit and osimertinib resistance in EGFR-mutant NSCLC. Cancer letters · 16 May 2026 PMID 42142703
- Altered Sphingolipid Metabolism is Associated with Osimertinib Resistance in Nonsmall-Cell Lung Cancer. Journal of proteome research · 16 Apr 2026 PMID 41988688
Unclassified: not yet indexed with MeSH (1)
- Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH). Cancer biology & medicine · 22 May 2026 PMID 42170792
Written from 19 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.